Richard W. Dugan
Director/Board Member chez VANDA PHARMACEUTICALS INC.
Fortune : 401 547 $ au 31/03/2024
Profil
Richard W.
Dugan is currently the Lead Independent Director at Vanda Pharmaceuticals, Inc. He previously held positions as Director at Middlebrook Pharmaceuticals, Inc. from 2003 to 2010, Director at Critical Therapeutics, Inc. from 2004 to 2008, and Director at Antisoma, Inc. He also served as Senior Partner at Ernst & Young LLP from 2001 to 2002.
Mr. Dugan obtained his undergraduate degree from The Pennsylvania State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/06/2023 | 97 700 ( 0,17% ) | 401 547 $ | 31/03/2024 |
Postes actifs de Richard W. Dugan
| Sociétés | Poste | Début |
|---|---|---|
| VANDA PHARMACEUTICALS INC. | Director/Board Member | 01/12/2005 |
Anciens postes connus de Richard W. Dugan
| Sociétés | Poste | Fin |
|---|---|---|
Middlebrook Pharmaceuticals, Inc.
 Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Director/Board Member | 03/08/2010 |
| Critical Therapeutics, Inc. | Director/Board Member | 04/11/2008 |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/09/2002 |
Antisoma, Inc.
 Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Director/Board Member | - |
Formation de Richard W. Dugan
| The Pennsylvania State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VANDA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
| Critical Therapeutics, Inc. | Health Technology |
Middlebrook Pharmaceuticals, Inc.
Middlebrook Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology MiddleBrook Pharmaceuticals, Inc. develops and commercializes anti-infective drug products. It operates mainly in prescription pharmaceuticals. MiddleBrook's main product is PULSYS. PULSYS technology offers the prolonged release and absorption of a drug. The company was incorporated in December 1999 and is headquartered in Westlake, TX. | Health Technology |
Antisoma, Inc.
Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Health Technology |
